$0.804
-0.004 (-0.48%)終値時点
ISPC のニュース
ISPC のイベント
iSpecimen Completes International Cancer Research Project
iSpecimen recently completed an international cancer research project involving hundreds of cancer blood specimens, with the samples shipped within three weeks of receiving the purchase order. The project involved the coordination of large-scale biospecimen sourcing and fulfillment on an accelerated timeline. Through its network of healthcare and research partners, iSpecimen coordinated the sourcing and collection of the required specimens and managed international fulfillment to meet the project's timeline.
iSpecimen Prices Public Offering at $1.30 per Share
iSpecimen announced the pricing of its public offering of approximately $5M of the company's common stock, and/or pre-funded warrants to purchase shares of common stock at a public offering price of $1.30 per share. The offering is expected to close on August 7. E.F. Hutton & Co. is acting as the exclusive placement agent in connection with the offering.
iSpecimen Files to Sell 488,290 Shares of Common Stock
iSpecimen files to sell 488,290 shares of common stock for holders
iSpecimen Inc Trading Halted, News Pending
iSpecimen Inc trading halted, news pending
iSpecimen Files to Sell 101M Shares of Common Stock
iSpecimen files to sell 101M shares of common stock for holders
関連記事
- CPI Report and the Stock Market: How to Read October 2026 Inflation Data Before the Fed DecidesOctober 2026 CPI lands Nov 10 with no year-over-year number and Fed hike odds near 80%. Learn how to read CPI, which stocks react, and how to plan for it.
- Are You Buying NVIDIA’s Earnings or Its CEO’s Perfect Image?An Alphio analysis of NVIDIA’s share-price timeline, operating results, governance uncertainty and upcoming earnings.
- Stock Market After the 2026 Midterms: What a Democratic Congress Means for InvestorsDemocrats swept Congress in the 2026 midterms. See how stocks reacted, what history says about post-midterm returns, and which sectors face new risks.
本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。






